Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered the public markets through the SPAC process, operating in the healthcare and life sciences sector with a focus on oncology therapeutics, specifically next-generation antibody-drug conjugate technology. The company filed a Form 10-Q with the SEC on August 16, 2021, accession number 0001206774-21-002187, reflecting its reporting obligations as a publicly registered entity. PKBO's listing brought a Korea-linked biopharma pipeline into the U.S. public market, a sector that saw notable SPAC activity during the 2020–2022 window. For full filing history, sponsor details, merger timeline, and deal-level analytics on PKBO and thousands of other SPAC transactions, sign up for complete access at SpacDesk.